130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
3 Completed Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
4 Completed A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MF59;   Biological: rgp120/HIV-1 SF-2
5 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: rgp120/HIV-1MN
6 Completed A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2
7 Completed A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
8 Completed Candidate HIV Vaccine
Condition: HIV Infections
Intervention: Drug: VRC-HIVDNA016-00-VP
9 Completed Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: HIV-1 gag DNA plus IL-12 DNA adjuvant;   Biological: CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine);   Biological: Sodium chloride injection (0.9%)
10 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
11 Active, not recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
12 Completed A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
Condition: HIV Infection
Interventions: Drug: Vaccination;   Drug: Placebo
13 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1;   Biological: TBC-3B Vaccine
14 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
15 Completed Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP
16 Completed A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: Lipid A, Monophosphoryl;   Biological: Lipid A, Liposome-encapsulated monophosphoryl;   Biological: Syntex adjuvant formulation;   Biological: MF59;   Biological: Threonyl Muramyl Dipeptide;   Biological: rgp120/HIV-1 SF-2;   Biological: MTP-PE/MF59
17 Completed Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
18 Completed A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Intervention: Biological: HIV-1 Peptide Immunogen, Multivalent
19 Unknown  Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
20 Completed Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years